Valganciclovir

Valganciclovir

Form: Tablet & Oral solution

Strength: Tab: 450 mg; Oral solution: 50 mg/mL

Reference Brands: Valcyte®

Category: Anti Viral

Valganciclovir Tablets are a potent antiviral used primarily to treat and prevent cytomegalovirus (CMV) infections, especially in immunocompromised patients, such as organ transplant recipients and individuals with HIV/AIDS. As a prodrug of ganciclovir, Valganciclovir offers improved oral bioavailability. Available in 450 mg strength, it is widely sourced by hospitals, pharmacies, and healthcare providers. On PharmaB2B platforms, buyers can connect with GMP-certified manufacturers and exporters for bulk supply of Valganciclovir Tablets. Ideal for global distributors seeking regulatory-compliant, high-quality products at competitive prices, PharmaB2B simplifies the procurement and sourcing of essential antiviral medications like Valganciclovir.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Zanamivir

Strength: 5 mg/blister

Form: Inhalation powder

Reference Brands: Relenza(EU & US)

View Details Get Enquiry
Oseltamivir Phosphate Capsule

Strength: Capsule- 30 mg, 45 mg, 75 mg; Oral Suspension - 6 mg/mL (reconstituted)

Form: Capsules and Oral solution

Reference Brands: Tamiflu(EU & US)

View Details Get Enquiry
Amantadine

Strength: Tab -100 mg; Capsule- 100 mg; Oral solution - 50 mg/5 mL; Extended-release capsule (ER) - 129 mg, 193 mg

Form: Tablet; Capsule; Oral Solution and ER Capsule

Reference Brands: Symmetrel(EU & US); Osmolex ER(US), Gocovri(US)

View Details Get Enquiry
Glecaprevir + Pibrentasvir

Strength: Glecaprevir- 100 mg + Pibrentasvir - 40 mg

Form: Tablet

Reference Brands: Mavyret (US); Maviret (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.